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Introduction
BIBT 986 is a dual inhibitor of factors Xa and IIa. The aim
of this study was to compare with placebo the effect of
three doses of BIBT 986 on coagulation, platelet activation
and inflammation.
Methods
This was a prospective, randomized, double-blind, pla-
cebo-controlled, parallel-group dose escalation trial in 48
healthy male volunteers. Participants received one of
three doses of BIBT 986 or placebo intravenously together
with a bolus infusion of 2 ng/kg lipopolysaccharide (LPS).
Results
BIBT 986 dose-dependently changed global coagulation
parameters and in vivo markers of thrombin generation
and action: BIBT 986 doses, which prolonged activated
partial thromboplastin time by 100%, completely sup-
pressed the LPS-induced increases in prothrombin frag-
ment, thrombin-antithrombin complexes and D-dimer,
which were 6.1, 14.5, and 3.5-fold in the placebo group,
respectively. BIBT 986 did not influence inflammation,
fibrinolysis, or platelet activation.
Conclusion
BIBT 986 is a potent anticoagulant in the human endotox-
emia model.
from 13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the 
Hungarian Society for Experimental and Clinical Pharmacology (MFT)
Vienna, Austria. 22–24 November 2007
Published: 14 November 2007
BMC Pharmacology 2007, 7(Suppl 2):A29 doi:10.1186/1471-2210-7-S2-A29
<supplement> <title> <p>13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT)</p> </title> <editor>Ernst Singer and Thomas Griesbacher</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="[http://www.biomedcentral.com/content/files/pdf/1471-2210-7-S2-full.pdf]">here</a></note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-7-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/7/S2/A29
© 2007 Leitner et al; licensee BioMed Central Ltd. 
